Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
Rhea-AI Summary
Agenus (NASDAQ: AGEN) announced that Dr. Steven O'Day, Chief Medical Officer, will participate in a panel at the William Blair Biotech Focus Conference 2021 on July 14, 2021. The panel discussion is titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” and will occur from 4:20 p.m. to 5:20 p.m. ET. The event will be webcast live on the Company's website, highlighting Agenus' commitment to advancing immuno-oncology therapies.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AGEN gained 2.97%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O’Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors.”
The panel will take place on Wednesday, July 14, 2021, from 4:20 p.m. to 5:20 p.m. ET. The event will be webcast live and may be accessed on the Company's website at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com
Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
When is Agenus' panel discussion at the William Blair Biotech Focus Conference 2021?
What is the main topic of the Agenus panel discussion?
Who will represent Agenus at the William Blair conference?
Where can I watch the Agenus panel discussion live?
What industry is Agenus involved in?
